Cargando…
Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir
We measured viral kinetics of SARS-CoV-2 Omicron infection in 36 mRNA-vaccinated individuals, 11 of whom were treated with nirmatrelvir-ritonavir (NMV-r). We found that NMV-r was associated with greater incidence of viral rebound compared to no treatment. For those that did not rebound, NMV-r signif...
Autores principales: | Dai, Eric Y., Lee, Kannon A., Nathanson, Audrey B., Leonelli, Ariana T., Petros, Brittany A., Brock-Fisher, Taylor, Dobbins, Sabrina T., MacInnis, Bronwyn L., Capone, Amelia, Littlehale, Nancy, Boucau, Julie, Marino, Caitlin, Barczak, Amy K., Sabeti, Pardis C., Springer, Michael, Stephenson, Kathryn E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387148/ https://www.ncbi.nlm.nih.gov/pubmed/35982651 http://dx.doi.org/10.1101/2022.08.04.22278378 |
Ejemplares similares
-
Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
por: Qiu, Chaochao, et al.
Publicado: (2023) -
Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022) -
Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023) -
Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023) -
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)